Monday, January 25, 2021
Home Latest Pharma-News Biogen to launch pioneering study with Apple watch and iphone

Biogen to launch pioneering study with Apple watch and iphone

January 11, 2021: “Biogen Inc. announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). 

The multi-year, observational research study will be launched later in 2021 and will enroll participants including young and aging adults with a range of cognitive performance.

- Advertisement -

Driven by the powerful technology in Apple Watch and iPhone and Biogen’s in-depth knowledge of neuroscience, the study’s primary objectives are to develop digital biomarkers to help monitor cognitive performance over time and identify early signs of MCI.

For aging adults, cognitive health is becoming increasingly recognized as an important component of overall health.

However, significant delays exist in identifying declines in cognitive health including MCI, which impacts approximately 15 – 20 percent of adults over the age of 65.

The onset of symptoms is often subtle, ranging from being easily distracted to memory loss, and can take months to years before cognitive decline comes to the attention of health care providers.

The virtual study allows adult users across the aging lifespan to join.

The study has been designed with customer privacy, control and transparency in mind as well as data security.

Participants, who can stop taking part in the study at any time, will complete a detailed consent form listing the collected data types and how each may be used and shared.

Data will be stored in an encrypted manner and in systems with strong security controls designed to protect the data.

“Cognitive decline can be an early symptom of neurodegenerative diseases and dementia.

The successful development of digital biomarkers in brain health would help address the significant need to accelerate patient diagnoses and empower physicians and individuals to take timely action,” said Michel Vounatsos, CEO at Biogen.

“For healthcare systems, such advancements in cognitive biomarkers from large-scale studies could contribute significantly to prevention and better population-based health outcomes, and lower costs to health systems.

Bringing together the best of neuroscience with the best of technology creates a wonderful prospect for patients and public health.”

“Working in collaboration with Biogen, we hope this study can help the medical community better understand a person’s cognitive performance by simply having them engage with their Apple Watch and iPhone,” said Jeff Williams, Apple’s chief operating officer.

“We’re looking forward to learning about the impact our technology can have in delivering better health outcomes through improved detection of declining cognitive health.”

“This is terrific news for all of us who are interested in our brain health,” said George Vradenburg, Chairman and Cofounder of UsAgainstAlzheimer’s, a patient-led non-profit pushing to prevent dementia through ongoing attention to brain health.

“Just as we today use new digital and mobile tools to help us monitor and improve our cardiovascular health, this new study will help us learn how to use those same tools to monitor and improve our brain health.

We have learned repeatedly that detecting disease at its earliest stage is our best bet to treat it effectively.

To that end, this exciting study could enable us to learn how to get early warning signs of cognitive decline which may be addressed through lifestyle and therapeutic changes designed to slow or stop the progression of brain disease.”

“Strategies that optimize brain health and improve cognitive function are the key to reducing the risk of dementia and this study has the potential to discover transformative ways to monitor and assess brain health,” said Nora Super, executive director of the Milken Institute Alliance to Improve Dementia Care.

“We are always eager to see technological innovation, and we are particularly interested in the user convenience of data collected through the use of everyday devices like Apple Watch and iPhone.

This type of innovation may enhance our understanding of the aging brain and therefore may ultimately help us understand how to maintain and improve brain health throughout adulthood.”

https://investors.biogen.com/news-releases/news-release-details/biogen-launch-pioneering-study-develop-digital-biomarkers

LEAVE A REPLY

Please enter your comment!
Please enter your name here

two + sixteen =

Most Popular

Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia

January 25, 2021: "AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult...

What is the process for Submission of Synopsis?

1.1 a. "Prior to submission of a thesis synopsis, a comprehensive assessment of the research work should be carried out by a...

COVAX Announces new agreement, plans for first deliveries

January 22, 2021: COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income...

FDA Approves OPDIVO® with CABOMETYX® as First-line Treatment for advanced Renal Cell Carcinoma

22 Jan 2021:  Bristol Myers Squibb announced that OPDIVO®(nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks...